Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside
- 1 January 1992
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 29 (3) , 173-177
- https://doi.org/10.1007/bf00686248
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Primary CNS lymphomaNeurology, 1990
- Pharmacokinetic Studies of Intermediate- to High-Dose 1-β-D-Arabinofuranosylcytosine in Children With Acute Leukemia and LymphomaThe Journal of Clinical Pharmacology, 1987
- Successful High-Dose Intravenous Cytarabine Treatment of Parenchymal Brain Involvement From Malignant LymphomaArchives of internal medicine (1960), 1986
- Alteration of the pharmacokinetics of high-dose ara-C by its metabolite, high ara-U in patients with acute leukemia.Journal of Clinical Oncology, 1983
- High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.1983
- Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C)Cancer, 1982
- A PILOT-STUDY OF HIGH-DOSE 1-BETA-D-ARABINOFURANOSYLCYTOSINE FOR ACUTE-LEUKEMIA AND REFRACTORY LYMPHOMA - CLINICAL-RESPONSE AND PHARMACOLOGY1982
- Variation in Sensitivity of DNA Synthesis to Ara‐C in Acute Myeloid LeukaemiaBritish Journal of Haematology, 1980
- Methotrexate: Distribution in Cerebrospinal Fluid after Intravenous, Ventricular and Lumbar InjectionsNew England Journal of Medicine, 1975
- Clinical pharmacology of l‐β‐D‐arabinofuranosyl cytosineClinical Pharmacology & Therapeutics, 1971